InMode Ltd has filed a complaint with the United States International Trade Commission alleging ILOODA’s SecretRF fractional radio frequency microneedling system, distributed in the United States by Cutera Inc, infringes U.S. Patent No. 10,799,285.
Additionally, InMode requested that the ITC initiates an investigation into ILOODA’s infringing imports and issue an exclusion order to bar importation of SecretRF, a media release from InMode Ltd explains.
“As a disrupter in medical aesthetic devices, InMode has committed significant research and development resources to the development of its differentiated RF technologies. Those efforts have led to an ever-expanding intellectual property portfolio, a fundamental component of InMode’s strategic plan to grow shareholder value. InMode will continue to develop efficacious minimally invasive and hands-free treatments using its patented technology and plans to vigorously defend its IP.”
— InMode’s Chief Technology Officer, Dr. Michael Kreindel
InMode develops electro-surgical bi-polar radiofrequency devices, designed for the face, body, and skin. In addition, it offers full-body fractional RF technology through the commercialization of the Morpheus8 Subdermal Adipose Remodeling (SARD) device.
[Source(s): InMode Ltd, PR Newswire]
Related Content:
InMode Receives U.S. Patent for Fractional RF Morpheus8
InMode Introduces Morpheus8 Body Multi-Pulse Burst Technology
New from InMode: Morpheus8 Platform and Morpheus8 Body Fractional Technology
